Omnes Capital's exits

Allegro Suite is a complete SaaS software solution running on mobiles, the web and kiosks. Ariane is present on four continents and has been rolled out at over 2,500 sites in 20 countries. Ariane has a full and unique range of products and software solutions geared to every type of hotel ranging from budget to five-star hotels and from independents to international groups. 

Thanks to its access to and control of merchandise and manufacturing, Adamence offers its customers the quality of a major jewellery brand at web prices.
Founded in 2005 and headquartered in Paris, Adamence now sells a full range of jewellery, from the top end of the market to the latest fashions.
The website gives users the option of creating their own designs so that they receive a fully personalised item.

Founded in 2000, Turtle Entertainment GmbH is the European market leader in electronic sports (eSports). Through the Electronic Sports League (ESL), Turtle operates in 35 countries across five continents. More than two million users have registered on the league portal available at www.esl.eu, which has over ten million unique visitors per month. This website is one of the busiest in Germany. Turtle Entertainment, which is headquartered in Cologne, has over 150 employees.

Founded in 2000, TEMIS helps organisations structure, manage and leverage their unstructured information assets. Luxid®, its flagship platform, extracts structured information from unstructured content and semantically enriches content with domain-specific metadata. This enables organisations not only to intelligently archive, manage, analyse, discover and share increasing volumes of information, but also to maximise the efficiency of their intensive Big Data analysis and discovery tasks such as business intelligence, customer voice and social media analysis and scientific discovery.

uniQure purchased the assets of AMT in April 2012, making it one of the world leaders in gene therapy research and development. Its Glybera® product is the first gene therapy drug to have gained marketing approval in Europe, and is used to treat adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD), a rare condition in which patients do not have the gene for an enzyme responsible for breaking down fats.

 uniQure is developing products to treat various other conditions such as Haemophilia B, acute intermittent porphyria (AIP) and Parkinson’s disease.
February 2014: uniQure (QURE) successfully completed its IPO on the Nasdaq, raising $82 million. 
Market capitalisation at IPO date: $300 million